Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2893MR)

This product GTTS-WQ2893MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2893MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8072MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ3905MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ8427MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ9011MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ5463MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ8211MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ12309MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ2425MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW